RESUMO
The British Association of Surgical Oncology [BASO] has set standards for services provision and provides an audit program for the breast clinics. This study is an audit based on retrospective data to examine and report the one-year performance of Breast clinic at Abbasi Shaheed Hospital, Karachi. Between October 2009 and September 2010,615 new and 1158 follow up in a total of 1773 patients visited Breast clinic for their breast symptoms. A specially designed Performa for breast diseases was filled on the first visit of all patients, which included each patient's detailed history, physical examination, investigations and diagnosis. Each Performa was reviewed for audit. The total number of patients visited Breast clinic at Abbasi Shaheed hospital was 1773 including 615 new and 1158 were follow-up cases.Majority of them were between 16 to 50 years of age group. There were 348 [56.58%] patients with breast lump out of which 300 [48.78%] turned out to be benign on further investigation and 48 [07.80%] were malignant. Breast pain was the presenting complaint in 144 [23.41%] patients while 33 [05.36%] patients presented with nipple discharge, 54 [08.78%] with breast abscess, 15 [02.43%] had atrophy breast, 06 [0.97%] had hy-pertrophied breast, 09 [01.46%] were with asymmetry of breast and 06 [0.97%] with eczema of nipples. The audit showed that 03 out of 07 performances based standard, according to British Association of Surgical oncology [BASO] were not met satisfactorily. It is concluded that multidisciplinary breast clinic in public hospital provides better services to the symptomatic breast patients on their first visit
RESUMO
In this study cutaneous toxicities associated With the administration of chemotherapy in combination are discussed. Rapidly growing cells are the targets of chemotherapy, so the skin, hair follicles, and nail matrix are frequently affected by chemotherapy. Chemotherapy skin reactions are more likely toxic than allergic reactions. There are numerous chemotherapy-induced cutaneous reactions that have beelfi described in the literature. In addition to a variety of miscellaneous reactions, 19 major cutaneous reactions were discussed in current study. This study was designed to evaluate the clinical spectrum of all cutaneous toxicities over two years in hospitalized and ambulatory patients in the Department of Pediatric oncology and to establish probable relationship between the reaction and suspected anticancer protocol with the help of WHO [World Health Organization] Common Toxicity Criteria by Grade. The data on the cutaneous toxicities were analyzed by percentile and ranking method The minimal [0.8%] cutaneous adverse effects monitored during the study were Petechiae, photosensitivity, pruritis, urticaria wound-infection, erythema multiforme, hand-foot skin reaction, injection site reaction, dry skin. Alopecia was the single most common [64.3%] adverse effect observed during the study, where as the pigmentary changes were the second most common [18.2%] adverse effect monitored. While these side effects are generally not life threatening, they can be a source of significant distress to patients especially alopecia